Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Bain Capital Life Sciences
Deal Size : $121.0 million
Deal Type : Series A Financing
Merida Biosciences Launches with $121M for Autoimmune Therapies
Details : The financing aims to advance the clinical development of company's lead candidate, which is being evaluated for the treatment of Graves Disease.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
April 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Bain Capital Life Sciences
Deal Size : $121.0 million
Deal Type : Series A Financing